KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) FCF Margin (2020 - 2025)

Aurinia Pharmaceuticals' FCF Margin history spans 6 years, with the latest figure at 59.13% for Q4 2025.

  • For Q4 2025, FCF Margin rose 892.0% year-over-year to 59.13%; the TTM value through Dec 2025 reached 47.84%, up 2908.0%, while the annual FY2025 figure was 47.84%, 2908.0% up from the prior year.
  • FCF Margin reached 59.13% in Q4 2025 per AUPH's latest filing, down from 60.41% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 63.05% in Q2 2025 to a low of 5872.76% in Q1 2021.
  • Average FCF Margin over 5 years is 353.11%, with a median of 15.7% recorded in 2023.
  • Peak YoY movement for FCF Margin: soared 6977391bps in 2021, then crashed -520bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 114.73% in 2021, then soared by 132bps to 36.28% in 2022, then dropped by -14bps to 31.07% in 2023, then soared by 62bps to 50.21% in 2024, then increased by 18bps to 59.13% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's FCF Margin are 59.13% (Q4 2025), 60.41% (Q3 2025), and 63.05% (Q2 2025).